Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Receivables (2021 - 2025)

Ensysce Biosciences (ENSC) has disclosed Receivables for 5 consecutive years, with $8.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables changed N/A to $8.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.9 million, a N/A change, with the full-year FY2024 number at $1.7 million, down 84.03% from a year prior.
  • Receivables was $8.9 million for Q3 2025 at Ensysce Biosciences, down from $10.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $10.9 million in Q2 2022 to a low of $1.7 million in Q4 2024.
  • A 5-year average of $6.6 million and a median of $8.9 million in 2025 define the central range for Receivables.
  • Peak YoY movement for Receivables: plummeted 84.03% in 2024, then skyrocketed 399.24% in 2025.
  • Ensysce Biosciences' Receivables stood at $2.9 million in 2021, then soared by 279.58% to $10.9 million in 2022, then decreased by 1.07% to $10.8 million in 2023, then tumbled by 84.03% to $1.7 million in 2024, then skyrocketed by 416.46% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Receivables are $8.9 million (Q3 2025), $10.6 million (Q2 2025), and $9.2 million (Q1 2025).